Abstract
Aim of this study was to compare the effect of valsartan and felodipine on blood pressure (BP), plasma leptin (L), insulin sensitivity and plasma norepinephrine (NE) in obese hypertensive patients. Ninty-six obese patients (body mass index [BMI] ≥30 kg/m2) with mild to moderate essential hypertension (diastolic blood pressure [DBP] >90 and <110 mmHg, as evaluated with an appropriately sized cuff) aged 31–60 years, were randomized to a valsartan (80 mg/day for 16 weeks; n=48) or felodipine (5 mg/day for 16 weeks; n=48) treatment group after a 2-week wash-out period. After the first 4 weeks of treatment there was a titration with dose-doubling in non responder patients (DBP > 90 mmHg). At the end of the placebo period and of active treatment period, BP and BMI were evaluated and a venous sample was drawn at the same hour in the morning to evaluate plasma L and NE. Insulin resistance index (HOMA-IR) was calculated. No dietary advice was prescribed. Both valsartan and felodipine significantly decreased BP values (-19.3/15 mmHg and -18.9/13.6 mmHg, respectively p<0.001 vs. placebo), with no difference between treatments. However, felodipine increased plasma NE (+124 pg/ml, +38.2%, p<0.05 vs. placebo and <0.01 vs. valsartan) and had no effect on L, body weight and HOMA-IR index, while valsartan did not modify NE and produced a significant reduction in L (-3.7 ng/ml, -10.1%, p<0.05 vs. placebo), BMI (-1.7 kg/m2, -4.7%, p<0.01 vs. placebo) and HOMA-IR index (-1.6, -20%, p<0.05 vs. placebo). These results suggest that in hypertensive obese subjects, treatment with valsartan might offer an advantage over treatment with felodipine, since valsartan may help to improve obesity-related disorders in addition to lowering BP.
Similar content being viewed by others
Article PDF
References
National Institute of Health : Clinical Guidelines on the Identification, Evaluation and Treatment of Overweight and Obesity in Adults: the Evidence Report (NIH publication 98–4083). Bethesda, National Institutes of Health, 1998, pp 7–33.
Visscher TL, Seidell JC : The public health impact of obesity. Annu Rev Public Health 2001; 22: 355–375.
McLellan F : Obesity rising to alarming levels around the world. Lancet 2002; 359: 1412.
Kenchaiah S, Evans JC, Levy D, et al: Obesity and the risk of heart failure. N Engl J Med 2002; 347: 305–313.
Eckel RH, Krauss RM, for the AHA Nutrition Committee : American Heart Association call to action: obesity as a major risk factor for coronary heart disease. Circulation 1998; 97: 2099–2100.
Grundy SM : Obesity, metabolic syndrome and coronary atherosclerosis. Circulation 2002; 105: 2696–2698.
Sowers JR : Obesity as a cardiovascular risk factor. Am J Med 2003; 115 ( Suppl 8A): 37S–41S.
Schuldner AR, Yang R, Gong DW : Resistin, obesity and insulin resistance: the emerging role of the adipocyte as an endocrine organ. N Engl J Med 2001; 345: 1345–1346.
Misra A, Garg A : Leptin: its receptor and obesity. J Invest Med 1996; 44: 540–548.
Nakagawa K, Higashi Y, Sasaki S, Oshima T, Matsuura H, Chayama K : Leptin causes vasodilation in humans. Hypertens Res 2002; 25: 161–165.
Barba G, Russo O, Siani A, et al: Plasma leptin and blood pressure in men: graded associaton independent of body mass and fat pattern. Obes Res 2003; 11: 160–166.
Eikelis N, Schlaich M, Aggarwal A, Kaye D, Esler M : Interactions between leptin and the human sympathetic nervous system. Hypertension 2003; 41: 1072–1079.
Guha PK, Villareal D, Reams GP, Freeman RH : Role of leptin in the regulation of body fluid volume and pressures. Am J Ther 2003; 10: 211–218.
Rahmouni K, Haynes WG : Leptin and the cardiovascular system. Recent Prog Horm Res 2004; 59: 225–244.
Aneja A, El-Atat F, McFarlane SI, Sowers JR : Hypertension and obesity. Recent Prog Horm Res 2004; 59: 169–205.
Matsuda K, Teragawa H, Fukuda Y, Nakagawa K, Higashi Y, Chayama K : Leptin causes nitric-oxide independent coronary artery vasodilation in humans. Hypertens Res 2003; 26: 147–152.
Hall JE : The kidney, hypertension and obesity. Hypertension 2003; 41: 625–633.
Ferrannini E, Natali A : Essential hypertension, metabolic disorders and insulin resistance. Am Heart J 1991; 121: 1274–1282.
Imazu M : Hypertension and insulin disorders. Curr Hypertens Rep 2002; 6: 477–482.
Nishina M, Kikichi T, Yamazaki H, Kameda K, Hiura M, Uchiyama M : Relationship among systolic blood pressure, serum insulin and leptin, and visceral fat accumulation in obese children. Hypertens Res 2003; 26: 281–288.
Remie R, Zaagsma J : A new technique for the study of vascular presynaptic receptors in freely moving rats. Heart Circ Physiol 1986; 251: 4463–4467.
Hjemdahl P : Plasma catecholamines as markers for sympatho-adrenal activity in human primary hypertension. Pharmacol Toxicol 1988; 63 ( Suppl 1): 27–31.
Umeda M, Kanda T, Murakami M : Effects of angiotensin II receptor antagonists on insulin resistance syndrome and leptin in sucrose-fed spontaneously hypertensive rats. Hypertens Res 2003; 26: 485–492.
Ficek J, Kokot F, Chudek J, Adamczak M, Ficek R, Wiecek A : Influence of antihypertensive treatment with perindopril, pindolol or felodipine on plasma leptin concentration in patients with essential hypertension. Horm Metab Res 2002; 34: 703–708.
Marckham A, Goa KL : Valsartan. A review of its pharmacology and therapeutic use in essential hypertension. Drugs 1997; 54: 299–311.
Saltiel E, Gray Ellrodt A, Monk JP, Langley MS : Felodipine: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in hypertension. Drugs 1988; 36: 387–428.
Remie R, Zaagsma J : A new technique for the study of vascular presynaptic receptors in freely moving rats. Heart Circ Physiol 1986; 251: 4463–4467.
Hjemdahl P : Plasma catecholamines as markers for sympatho-adrenal activity in human primary hypertension. Pharmacol Toxicol 1988; 63 ( Suppl 1): 27–31.
Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC : Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412–419.
Lansang MC, Williams GH, Carrol J : Correlation between the glucose clamp technique and the Homeostasis Model Assessment in hypertension. Am J Hypertens 2001; 14: 51–53.
Parhami F, Tintut Y, Ballard A, et al: Leptin enhances the calcification of vascular cells: artery wall as a target of leptin. Circ Res 2001; 88: 954–960.
Oda A, Taniguchi T, Yokoyama M : Leptin stimulates rat aortic smooth muscle cell proliferation and migration. Kobe J Med Sci 2001; 47: 141–150.
Singhal A, Farooqi IS, Cole TJ, et al: Influence of leptin on arterial distensibility: a novel link between obesity and cardiovascular disease. Circulation 2002; 106: 1919–1924.
Kuwamura T, Yoshida K, Sugawara A, et al: Impact of exercise and angiotensin converting enzyme inhibition on tumor necrois factor-α and leptin in fructose-fed hypertensive rats. Hypertens Res 2002; 25: 927–938.
Barton M, Carmona R, Ortmann J, Krieger JE, Traupe T : Obesity-associated activation of angiotensin and endothelin in the cardiovascular system. Int J Biochem Cell Biol 2003; 35: 826–837.
Ailhaud G, Fukamizu A, Massiera F, Negrel R, Saint-Mark P, Teboul M : Angiotensinogen, angiotensin II and adipose tissue development. Int J Obes Relat Metab Disord 2000; 24 ( Suppl 4): S33–S35.
Giacchetti G, Falcia E, Falcia, et al: Gene expression of angiotensinogen in adipose tissue of obese patients. Int J Obes Relat Metab Disord 2000; 24 ( Suppl 2): S142–S143.
Laakso M, Karjalaainen L, Lempiainen-Kuosa P : Effects of losartan on insulin sensitivity in hypertensive subjects. Hypertension 1996; 28: 392–396.
Moan A, Hoieggen A, Seljeflot I, Risanger T, Arnesen H, Kjeldsen SE : The effect of angiotensin II receptor antagonism with losartan on glucose metabolism and insulin sensitivity. J Hypertens 1996; 14: 1093–1097.
Fogari R, Zoppi A, Corradi L, Lazzari P, Mugellini A, Lusardi P : Comparative effects of lisinopril and losartan on insulin sensitivity in the treatment of non diabetic hypertensive patients. Br J Clin Pharmacol 1998; 46: 467–471.
Iimura O, Shimamoto K, Matsuda K, et al: Effects of angiotensin receptor antagonist and angiotensin converting enzyme inhibitor on insulin sensitivity in fructose fed hypertensive rats and essential hypertensives. Am J Hypertens 1995; 8: 353–357.
Moan A, Hoieggen A, Nordby G, Eide IK, Kjeldsen SE : Effects of losartan on insulin sensitivity in severe hypertension: connections through sympathetic nervous system activity. J Hum Hypertens 1995; 9 ( Suppl 5): S45–S50.
Leenen FH, Holliwell D : Antihypertensive effect of felodipine associated with persistent sympathetic activation and minimal regression of left ventricular hypertrophy. Am J Cardiol 1992; 69: 639–645.
Hjemdahl P, Wallen NH : Calcium antagonist treatment, sympathetic activity and platelet function. Eur Heart J 1997; 18 ( Suppl A): A36–A50.
Fogari R, Zoppi A, Corradi L, Preti P, Malamani GD, Mugellini A : Effects of different dihydropyridine calcium antagonists on plasma norepinephrine in essential hypertension. J Hypertens 2000; 18: 1871–1875.
Grassi G, Esler M : How to assess sympathetic activity in humans. J Hypertens 1999; 17: 719–734.
Mancia G, Grassi G, Giannattasio C, Serravalle G : Sympathetic activation in the pathogenesis of hypertension and progression of organ damage. Hypertension 1999; 34: 724–728.
Palatini P : Sympathetic overactivity in hypertension: a risk factor for cardiovascular disease. Curr Hypertens Rep 2001; 3 ( Suppl 1): S3–S9.
Itoh K, Imai K, Masuda T, et al: Weight loss in obese subjects reduced blood pressure and the norepinephrine excretion in only hypertensive group. J Hypertens 1998; 16 ( Suppl 2): S152.
Klein S, Coppack SW, Mohamed-Ali V, Landt M : Adipose tissue leptin production and plasma leptin kinetics in humans. Diabetes 1996; 45: 984–987.
Van Harmelen V, Reynisdottiv S, Eriksson P, et al: Leptin secretion from subcutaneous and visceral adipose tissue in women. Diabetes 1998; 47: 913–917.
Considine RV, Sinha MK, Heiman MI, et al: Serum immunoreactive leptin concentrations in normal-weight and obese humans. N Engl J Med 1996; 334; 292–295.
Segal KR, Landt M, Klein S : Relationship between insulin sensitivity and plasma leptin concentration in lean and obese men. Diabetes 1996; 45: 988–991.
Mohamed-Ali V, Pinkney JH, Panahloo A, et al: Relationships between plasma leptin and insulin concentrations, but not insulin resistance, in non-insulin-dependent (Type 2) diabetes mellitus. Diabet Med 1997; 14: 376–380.
Agata J, Masuda A, Takeda M, et al: High plasma immunoreactive leptin level in essential hypertension. Am J Hypertens 1997; 10: 1171–1174.
Itoh K, Imai K, Masuda T, et al: Relationship between changes in serum leptin levels and blood pressure after weight loss. Hypertens Res 2002; 25: 881–886.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Fogari, R., Derosa, G., Zoppi, A. et al. Comparison of the Effects of Valsartan and Felodipine on Plasma Leptin and Insulin Sensitivity in Hypertensive Obese Patients. Hypertens Res 28, 209–214 (2005). https://doi.org/10.1291/hypres.28.209
Received:
Accepted:
Issue date:
DOI: https://doi.org/10.1291/hypres.28.209
Keywords
This article is cited by
-
Valsartan Versus Amlodipine Effect on Left Ventricular Multidirectional Deformation and Adipocytokines Levels in Hypertensive Patients: Speckle Tracking Echocardiography
High Blood Pressure & Cardiovascular Prevention (2020)
-
Effects of GLP-1 in the Kidney
Reviews in Endocrine and Metabolic Disorders (2014)
-
Brain renin–angiotensin system in the nexus of hypertension and aging
Hypertension Research (2013)
-
Angiotensin II type 1 receptor blockers improve insulin sensitivity in patients with schizophrenia being treated with olanzapine
Psychopharmacology (2011)
-
Weight loss and hypophagia after high-dose AT1-blockade is only observed after high dosing and depends on regular leptin signalling but not blood pressure
Naunyn-Schmiedeberg's Archives of Pharmacology (2011)
